Endevica Bio was formed in 2009 by Dr. Kenneth Gruber.     Dr. Gruber wanted to create synthetic peptides that would show druglike characteristics. He was successful in his mission, and the company has been awarded several patents and SBIR grants because of his pioneering work.  

Endevica Bio’s synthetic peptides are quite stable in plasma, have predictable pharmacokinetics, and can be engineered to cross the blood brain barrier.  These desirable characteristics form the platform that we are using for new drug design.  

Our Pipeline

TCMCB07 Cachexia Therapeutic 

Our lead compound has successfully completed dosing in Phase 1 human trials.  The trials show that B07 appears safe and well-tolerated.  

“B07” has been manufactured successfully at multiple sites and has a scalable manufacturing process.  Formulations are straightforward and shelf-stable.  Endevica Bio is working with teams of regulatory and scientific consultants to build our Clinical Development Plan.  

Endevica continues to commission preclinical trials at CROs around the world to better understand dose-specificity on our mechanism of action, as well as the way that our therapeutic will be used with other drugs and in different clinical situations.  

Early-stage drug development  

The company is working on three new nondisclosed targets for its internal pipeline.  Leveraging the platform design technologies created by Dr. Gruber, we expect to rapidly move these new candidates into IND-enabling trials.  Disclosures will be made as the drugs approach their Phase 1 trials.

Scroll to Top